Symposia: Multiple Myeloma: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Research, Clinical trials, Combination therapy, Clinical Practice (Health Services and Quality), Translational Research, CHIP, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Research, Clinical trials, Combination therapy, Clinical Practice (Health Services and Quality), Translational Research, CHIP, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Biological Processes, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Pacific Ballroom Salons 21-22
(Marriott Marquis San Diego Marina)
Moderators:
Phoebe Joy Ho, MBBS, Royal Prince Alfred Hospital and University of Sydney
and
Rahul Banerjee, MD, FACP, University of California, San Francisco
Disclosures:
Ho: Novartis: Other: Research support on medical writing. Banerjee: Adaptive; BMS; Caribou Biosciences; Genentech; GSK; JNJ / Janssen; Karyopharm; Legend Biotech; Pfizer; Sanofi; SparkCures: Consultancy; Abbvie; JNJ; Novartis; Pack Health; Prothena; Sanofi: Research Funding.
This oral session is dedicated to optimizing outcomes for patients receiving anti-BCMA CAR-T and bispecific antibody (BsAb) T cell engager therapies. The first presentation examines how prior high-dose melphalan with autologous stem cell transplantation (HDM/ASCT) can adversely affect progression-free survival (PFS) in patients undergoing BCMA-directed CAR T-cell therapy, adding to the ongoing discussion about treatment sequencing in the CAR-T era. The second and third talks address strategies to mitigate complications associated with T cell redirection therapies, such as prolonged cytopenias and infections, which are clinically significant. Collectively, these presentations aim to enhance patient outcomes in the context of anti-BCMA T cell redirection therapies.
2:15 PM
2:30 PM
2:45 PM
3:00 PM
3:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH